Arginine Therapy for Lung Diseases
Nitric oxide (NO) is produced by a family of isoenzymes, nitric oxide synthases (NOSs), which all utilize L-arginine as substrate. The production of NO in the lung and airways can play a number of roles during lung development, regulates airway and vascular smooth muscle tone, and is involved in inf...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-03-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.627503/full |
| _version_ | 1818734002027102208 |
|---|---|
| author | Jeremy A. Scott Harm Maarsingh Fernando Holguin Hartmut Grasemann |
| author_facet | Jeremy A. Scott Harm Maarsingh Fernando Holguin Hartmut Grasemann |
| author_sort | Jeremy A. Scott |
| collection | DOAJ |
| description | Nitric oxide (NO) is produced by a family of isoenzymes, nitric oxide synthases (NOSs), which all utilize L-arginine as substrate. The production of NO in the lung and airways can play a number of roles during lung development, regulates airway and vascular smooth muscle tone, and is involved in inflammatory processes and host defense. Altered L-arginine/NO homeostasis, due to the accumulation of endogenous NOS inhibitors and competition for substrate with the arginase enzymes, has been found to play a role in various conditions affecting the lung and in pulmonary diseases, such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), pulmonary hypertension, and bronchopulmonary dysplasia. Different therapeutic strategies to increase L-arginine levels or bioavailability are currently being explored in pre-clinical and clinical studies. These include supplementation of L-arginine or L-citrulline and inhibition of arginase. |
| first_indexed | 2024-12-17T23:58:26Z |
| format | Article |
| id | doaj.art-03e7bdb58bdc4a6d9640c485148f9cf6 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-17T23:58:26Z |
| publishDate | 2021-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-03e7bdb58bdc4a6d9640c485148f9cf62022-12-21T21:28:01ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-03-011210.3389/fphar.2021.627503627503Arginine Therapy for Lung DiseasesJeremy A. Scott0Harm Maarsingh1Fernando Holguin2Hartmut Grasemann3Occupational and Environmental Health, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, CanadaDepartment of Pharmaceutical Sciences, Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL, United StatesDivision of Pulmonary Sciences and Critical Care, University of Colorado, Aurora, CO, United StatesDivision of Respiratory Medicine, Department of Paediatrics and Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, ON, CanadaNitric oxide (NO) is produced by a family of isoenzymes, nitric oxide synthases (NOSs), which all utilize L-arginine as substrate. The production of NO in the lung and airways can play a number of roles during lung development, regulates airway and vascular smooth muscle tone, and is involved in inflammatory processes and host defense. Altered L-arginine/NO homeostasis, due to the accumulation of endogenous NOS inhibitors and competition for substrate with the arginase enzymes, has been found to play a role in various conditions affecting the lung and in pulmonary diseases, such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), pulmonary hypertension, and bronchopulmonary dysplasia. Different therapeutic strategies to increase L-arginine levels or bioavailability are currently being explored in pre-clinical and clinical studies. These include supplementation of L-arginine or L-citrulline and inhibition of arginase.https://www.frontiersin.org/articles/10.3389/fphar.2021.627503/fullairway hyperresponsivenessremodelingchronic obstructive pulmonary deseasecystic fibrosisPulmonary hypertensionasthma |
| spellingShingle | Jeremy A. Scott Harm Maarsingh Fernando Holguin Hartmut Grasemann Arginine Therapy for Lung Diseases Frontiers in Pharmacology airway hyperresponsiveness remodeling chronic obstructive pulmonary desease cystic fibrosis Pulmonary hypertension asthma |
| title | Arginine Therapy for Lung Diseases |
| title_full | Arginine Therapy for Lung Diseases |
| title_fullStr | Arginine Therapy for Lung Diseases |
| title_full_unstemmed | Arginine Therapy for Lung Diseases |
| title_short | Arginine Therapy for Lung Diseases |
| title_sort | arginine therapy for lung diseases |
| topic | airway hyperresponsiveness remodeling chronic obstructive pulmonary desease cystic fibrosis Pulmonary hypertension asthma |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2021.627503/full |
| work_keys_str_mv | AT jeremyascott argininetherapyforlungdiseases AT harmmaarsingh argininetherapyforlungdiseases AT fernandoholguin argininetherapyforlungdiseases AT hartmutgrasemann argininetherapyforlungdiseases |